RxDoctor Payments Data

Robert George

Family · Asheboro, NCNPI 1346754116

Payments from drug & device makers

$11,577in general payments, 2019–2025

Across 723 payments — averaging $16.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Lilly USA, LLC$1K
  • Novo Nordisk$950
  • AstraZeneca$480
  • Organogenesis Inc.$476
  • Eisai Inc.$352
  • plus $6K from 54 others

What the payments were for

  • Food & beverage$11,44999%
  • Education$1281%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie152$1,871
Lilly USA, LLC67$1,015
Novo Nordisk68$950
AstraZeneca(2 entities)26$480
Organogenesis Inc.3$476
Eisai Inc.20$352
Pfizer23$346
GSK26$333
Alkermes, Inc.14$295
Novartis17$269
Merck14$250
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC16$237
Sunovion Pharmaceuticals Inc.25$235
Bayer12$214
Otsuka America Pharmaceutical, Inc.10$205
Lundbeck LLC10$183
Teva Pharmaceuticals USA, Inc.11$182
Amgen12$177
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)10$166
Johnson & Johnson10$165
Takeda Pharmaceuticals U.S.A., Inc.9$149
Sanofi-aventis U.S. LLC8$148
Boehringer Ingelheim8$144
Xeris Pharmaceuticals, Inc.9$138
Ironwood Pharmaceuticals, Inc6$130
Axsome Therapeutics, Inc.6$124
Astellas Pharma US Inc3$117
Abbott5$99
Corcept Therapeutics6$99
Vanda Pharmaceuticals Inc.5$95
Medtronic4$91
Sumitomo Pharma America, Inc.6$90
Mylan Specialty L.p.4$85
Ultragenyx Pharmaceutical Inc.4$81
Verona Pharma, Inc.4$80
Biohaven Pharmaceuticals, Inc.4$79
UCB, Inc.3$73
Esperion Therapeutics, Inc.4$73
Shield Therapeutics Inc5$71
Amarin Pharma, Inc.5$69
Idorsia Pharmaceuticals US Inc4$67
GRT US Holding, Inc.3$66
Neurelis, Inc.3$56
Paratek Pharmaceuticals, Inc.3$54
Phathom Pharmaceuticals, Inc.4$51
Neurocrine Biosciences, Inc.3$51
Ardelyx, Inc.3$50
Hikma Pharmaceuticals USA3$45
Corium, LLC4$43
Biohaven Pharmaceutical Holding Company Ltd.2$42
Currax Pharmaceuticals LLC2$40
Dexcom, Inc.2$39
Exact Sciences2$38
Arbor Pharmaceuticals, Inc.2$37
Viatris Specialty LLC2$35
Collegium Pharmaceutical, Inc.2$29
Tolmar, Inc.2$28
CMP Pharma, Inc.2$27
Kowa Pharmaceuticals America, Inc.2$26
Otsuka Pharmaceutical Development & Commercialization, Inc.1$25

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,577 in reported general payments places this provider in the 95th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$4,619
Medicare patients
90
Services billed
113

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide89$102,572
FarxigaDapagliflozin Propanediol71$71,539
OzempicSemaglutide50$63,942
TrulicityDulaglutide31$62,253
VraylarCariprazine Hcl28$41,912
EliquisApixaban32$37,541
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$36,928
LinzessLinaclotide38$35,773
CreonLipase/Protease/Amylase19$34,787
Xtampza ErOxycodone Myristate36$33,964
XareltoRivaroxaban29$30,107
Tresiba Flextouch U-100Insulin Degludec52$27,944
RybelsusSemaglutide15$22,196
JardianceEmpagliflozin24$19,549
Breo ElliptaFluticasone/Vilanterol23$18,499

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$1,015$164,825120 claims
AbbVieVraylar, Linzess, Creon, Synthroid$1,871$114,005103 claims
Novo NordiskOzempic, Rybelsus$950$86,13865 claims
AstraZenecaFarxiga, Symbicort$480$83,81398 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$333$73,80778 claims
Johnson & JohnsonXarelto, Invokana$165$47,23946 claims
PfizerEliquis, Premarin$346$44,27745 claims
Collegium Pharmaceutical, Inc.Xtampza Er$29$33,96436 claims
Boehringer IngelheimJardiance$144$19,54924 claims
MerckJanumet Xr$250$15,12116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,522 family providers in North Carolina.

Other family in Asheboro

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →